Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors
- 1 September 2003
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 90 (3) , 610-618
- https://doi.org/10.1016/s0090-8258(03)00373-1
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Paclitaxel and Platinum Chemotherapy for Malignant Mixed Mullerian Tumors of the OvaryGynecologic Oncology, 2002
- Liposomal Doxorubicin in Ovarian, Peritoneal, and Tubal Carcinoma: A Retrospective Comparative Study of Single-Agent DosagesGynecologic Oncology, 2001
- Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus TopotecanJournal of Clinical Oncology, 2001
- The Clinical Utility of Liposomal Doxorubicin in Recurrent Ovarian CancerGynecologic Oncology, 2001
- Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancerAnti-Cancer Drugs, 2000
- Phase II Study of Liposomal Doxorubicin in Platinum- and Paclitaxel-Refractory Epithelial Ovarian CancerJournal of Clinical Oncology, 2000
- Phase 2 Trial of Liposomal Doxorubicin (40 mg/m2) in Platinum/Paclitaxel-Refractory Ovarian and Fallopian Tube Cancers and Primary Carcinoma of the PeritoneumGynecologic Oncology, 2000
- Estimation of Variance for Harmonic Mean Half-LivesJournal of Pharmaceutical Sciences, 1985
- Preparation of mean drug concentration-time curves in plasma. A study on the frequency distribution of pharmacokinetic parameters.CHEMICAL & PHARMACEUTICAL BULLETIN, 1985
- Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous InfusionAnnals of Internal Medicine, 1982